# Postoperative Pneumonia Characteristics following Pulmonary Thromboendarterectomy (PTE)

## Northwestern Medicine®

Shardul N. Rathod, MPH, CIC<sup>1</sup>, Pamela Ropski, MD<sup>2</sup>, Jakub Glowala, MD<sup>2</sup>, Charles M. Quinn, BS<sup>2</sup>, Alyssa Stamper, BS<sup>2</sup>, Maureen K. Bolon, MD<sup>2</sup>, Daniel Schimmel, MD<sup>2</sup>, S. Chris Malaisrie, MD<sup>2</sup>, Mike J. Cuttica, MD, MS<sup>2</sup>, Ruben Mylvaganam, MD, MS<sup>2</sup> <sup>1</sup>Northwestern Memorial Hospital, Chicago, IL, USA, <sup>2</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, USA

## Background

Pulmonary thromboendarterectomy (PTE), the gold standard treatment for chronic thromboembolic hypertension (CTEPH), can be complicated by reperfusion lung injury (RPLI) in up to 40-50% of cases.<sup>1</sup>

Unique features of this highly specialized surgery may predispose patients to increased risk of postoperative pneumonia (PNA) in addition to RPLI.

Rates of PNA following cardiac surgery range from 2-10%, but its rates following PTE are not as well understood with rates ranging from 17-35%.<sup>1</sup>

This study aims to describe the incidence of suspected/confirmed post-PTE PNA compared to RPLI, assess the diagnostic and clinical characteristics, and evaluate the outcomes of these groups.

### Methods

### **CTEPH Registry**

A research registry of CTEPH and Venous Thromboembolic Disease (VTED) subjects was created at Northwestern Memorial Hospital.

### Definitions

radiographic infiltrates in region of **RPLI**: presence of endarterectomized tissue and hypoxemia within 48-72 hours following PTE.

Postoperative PNA: signs/symptoms (fever, leukocytosis, infiltrates on x-ray) within 7 days following PTE.

<u>Microbiologically confirmed PNA</u>: positive culture from a lower respiratory tract specimen with a quantitative threshold of  $\geq 10^4$ cfu/mL.

### Data Analysis

Performed using R Studio version 4.3.1. with statistical significance defined as a p-value < 0.05.

### Table 1: Baseline chara Demographics


Age in years Female Sex Body Mass Index (BMI) Race White Black Unknown/Not Repo Ethnicity Not Hispanic or Lati Hispanic or Latino History of Pneumonia **CTEPH Comorbidities** Antiphospholipid Syndr Splenectomy Ventriculoatrial (VA) Sh Prior Venous Thromboo Obesity Additional Operative P Preoperative Hemody Mean Right Atrial Press Mean Pulmonary Arter Pulmonary Capillary W Cardiac Index (CI), L/mi Pulmonary Vascular Re **Clinical Risk Assessme** NYHA FC 6MWD, m BNP, pg/mL Pulmonary Function Forced Vital Capacity ( Forced Expiratory Volu

FVC/FEV<sub>1</sub> ratio Total Lung Capacity (TL DLCO

Values expressed as media

Figure 1: Characteristics breakdown of subjects w PNA, and subjects with m

Results		Results	
racteristics of the study population (n=75)		Table 2: Microbiologic data for subjects with diagnoses of RPLI, PNA, and microbiologically confirmed PNA	
		RPLI Rate of Documented RPLI	21 (28)
	56 (46-64) 45 (60)	History of PNA in prior 180 days	21 (28) 4 (19)
11)	33 (28-40)	Time between PTE and RPLI, days	2 (1,3)
	33 (20 40)	PNA	
	45 (60)	Rate of Documented PNA	16 (21)
	25 (33)	History of PNA in prior 180 days	0 (0)
ported	5 (7)	Rate of Microbiologically Confirmed PNA	5 (7)
		Time between PTE and PNA, days	5 (3,5)
itino	70 (75)	Diagnostic Sampling Rate of Diagnostic Sampling Performed	9 (42.9)
a (PNA) Six Months Prior PTE	5 (7) 4 (5)	Rate of Positive BAL/NBBAL	5 (55.6)
	4 (5)	Haemophilus parainfluenzae	1 (20.0)
ndrome (APLS)	6 (8.0)	Pseudomonas aeruginosa	2 (40.0)
	3 (4.0)	Staphylococcus aureus	2 (40.0)
Shunt	1 (1.3)	Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)	1 (50.0)
ooembolism (VTE)	61 (81.3)	Postoperative Antibiotics in Post-PTE PNA Subjects	
	47 (62.7)	Postoperative Antibiotics	
Procedure	34 (45.3)	Cefepime	3 (60.0)
lynamics		Ceftriaxone	1 (20.0)
essure (mRAP), mmHg	$10.2\pm 6.0$	Piperacillin-tazobactam	1 (20.0)
ery Pressure (mPAP), mmHg	45.8 ± 12.0	Vancomycin	1 (20.0)
Wedge Pressure (PCWP), mmHg	12.7 ± 5.0	Duration of Antibiotics in Days	7.5 (2.5,8.8)
$min/m^2$	$2.3 \pm 0.6$	Values expressed as median (IQR), n (%), and mean ± SD.	
Resistance (PVR), Dynes.sec.cm <sup>-5</sup>	610.5 ± 336	<sup>30</sup> Figure 2: (A) Subject outcomes related to hospital	Т
nents	2.8	length of stay (LOS), ICU LOS, and mechanical	
	2.0 311 ± 176	ventilation (IVIV) duration, (B) Subject outcomes	
	252.6 ± 333.7	related to WBC count as postoperative day one in (1)	
Tests (PFTs)		201 normal post-PTE, (2) post-PTE PNA, (3) post-PTE RPLI (+) and PNA (+) groups. 15.	
r (FVC)	$79.8 \pm 14.0$		
lume <sub>1</sub> (FEV <sub>1</sub> )	$74.4 \pm 14.4$	S RPLI (-) PNA (-)	RPLI (-) PNA (-) RPLI (-) PNA (+)
	0.78	RPLI (-) PNA (+) X   RPLI (+) PNA (-) Image: state	RPLI (+) PNA (-)
TLC)	$87.0\pm16.4$	RPLI (+) PNA (+)	RPLI (+) PNA (+)
	$64.4\pm17.6$	10- Ŭ	
dian (IQR), n (%), and mean ± SD.		* p=0.00	
RPLI (+)			
	PNA (+)		
	21%	Hospital LOS ICU LOS MV Duration PO	DD1 WBC
ics of total cohort (n=75) including a		Discussion	
with and without RPLI, subjects with microbiologically confirmed PNA.	RPLI (-)	PNA is a common finding in the setting of RPLI at the time of PTE.	
	72%	Correlation between RPLI and PNA emphasizes need for comprehensive appro	ach in evaluation early
		detection, and management of PNA in patients with RPLI post-PTE.	
		References	



<sup>1</sup>Kerr KM, Auger WR, Marsh JJ, et. Al. Efficacy of methylprednisolone in preventing lung injury following pulmonary thromboendarterectomy. *Chest*. 2012;141(1):27-35.